Form 4: Amarin Corp Chief Scientific Officer Reports Stock Transactions Following RSU Vesting

Amarin's Chief Scientific Officer, Steven B. Ketchum, reported multiple transactions involving the acquisition and disposal of ordinary shares following the vesting of restricted stock units (RSUs).

Summary

• Steven B. Ketchum, Chief Scientific Officer of Amarin Corp, reported several transactions related to the vesting of his Restricted Stock Units (RSUs).
• On January 30, 2025, 51,500 RSUs vested due to the achievement of a performance-based milestone, resulting in the acquisition of 51,500 ordinary shares.
• Also on January 30, 2025, 28,382 shares were withheld to cover tax liabilities related to the vesting of the RSUs at a price of $0.62 per share.
• On January 31, 2025, additional RSUs vested from previous grants, resulting in the acquisition of 34,566, 44,933, and 38,667 ordinary shares.
• Correspondingly, 19,197, 24,833, and 21,093 shares were withheld on January 31, 2025, to cover tax liabilities at a price of $0.62 per share.
• The transactions resulted in a net increase in the number of ordinary shares beneficially owned by Mr. Ketchum.

Sentiment

Score: 7

Explanation: The document reflects routine insider transactions related to RSU vesting, which is generally a positive sign of company performance and executive alignment. There are no indications of negative sentiment.

Positives

• The vesting of RSUs indicates that performance milestones were met, which is a positive sign for the company.
• The increase in share ownership by a key executive could be seen as a positive signal of confidence in the company's future.

Negatives

• The withholding of shares to cover tax liabilities resulted in a reduction of the total shares received by the executive.

Risks

• The value of the shares is subject to market fluctuations, which could impact the overall value of the vested RSUs.
• The vesting of RSUs is dependent on continued service with the company, which could be a risk if the executive were to leave.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in publicly traded companies. It reflects the compensation structure for executives, often including equity-based awards.

Comparison to Industry Standards

• The use of RSUs as part of executive compensation is a standard practice in the pharmaceutical industry and other sectors.
• The vesting schedules and performance-based milestones are typical for RSU grants.
• Companies like Regeneron, Biogen, and Gilead also use similar equity-based compensation plans for their executives.

Stakeholder Impact

• Shareholders may view the vesting of RSUs as a positive sign of company performance and executive alignment.
• Employees may see the vesting of RSUs as a positive sign of the company's commitment to its employees.

Key Dates

Keywords

Amarin, RSU, Restricted Stock Units, Stock Incentive Plan, Share Vesting, Form 4, Insider Trading, Steven B. Ketchum, Chief Scientific Officer, Ordinary Shares